Adaptimmune
IPOArming cells. Against cancer. For good.
Public · Philadelphia, United States · Founded 2008 · $104.0M raised
- Headquarters
- Philadelphia
- Employees
- 201–500
- Founded
- 2008
- Business Model
- B2B
- Website
- adaptimmune.com
- Total Funding
- $104.0M
- Last Round
- $104.0M Venture RoundSep 2014
- Rounds
- 1
- Type
- Public
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
About
Founded in 2008, Adaptimmune develops novel T-cell receptor (TCR-T) immunotherapies for cancer treatment. The company pioneered the first FDA-approved engineered cell therapy for solid tumors (TECELRA). Headquartered in Philadelphia with UK operations, it employs approximately 300-400 people across its integrated cell therapy platform.
Summary
Adaptimmune is a Biotech company based in Philadelphia, United States, founded in 2008. It has raised $104.0M in total across 1 round, most recently a $104.0M Venture Round in Sep 2014. Investors include Hercules Capital, New Enterprise Associates and F-Prime Capital.
Tech & App Stack
4 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding & Exit History
May 2024
Sign up to see all 3 events
Funding: Venture Round. Amounts, valuations, and investors where available.
Investors
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/adaptimmune"><img src="https://indexed.vc/api/badge/company/adaptimmune" alt="Adaptimmune on Indexed.vc" width="260" height="76" /></a>